The Timing of Granulocyte Colony-Stimulating Factor in Hematopoietic Stem Cell Transplant in the Pandemic

Basit Öğe Kaydı
dc.authorscopusid58117370900
dc.authorscopusid56545735000
dc.authorscopusid57189243089
dc.authorscopusid58370887900
dc.authorscopusid56370690600
dc.authorscopusid6602557128
dc.contributor.authorKaçmaz, Murat
dc.contributor.authorBaşci, Semih
dc.contributor.authorYiğenoğlu, Tuğçe Nur
dc.contributor.authorÇakar, Merih Kizil
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorAltuntaş, Fevzi
dc.date.accessioned2024-09-19T15:41:24Z
dc.date.available2024-09-19T15:41:24Z
dc.date.issued2023
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractGranulocyte-colony stimulating factors (G-CSF) are used to shorten the duration of neutropenia after hematopoietic cell transplantation (HCT). However, there is no consensus on which days treatment should be started post-transplantation during the COVID-19 pandemic. In this study, we looked at the influence of G-CSF on clinical outcomes on the fifth (G-CSFd5) and tenth (G-CSFd10) days following allo-HCT. Our study includes the data of 60 patients (G-CSFd5, n=28 vs G-CSFd10, n=32) who underwent HCT with the diagnosis of acute lymphoblastic leukemia (ALL) between 2015 and 2022. Primary outcome is the effect of G-CSF on hospital stay. Secondary outcomes are the development and duration of febrile neutropenia (FEN), neutrophil engraftment (NE), platelet engraftment (PE), engra ftment syndrome (ES), acute graft versus host disease (aGVHD), cytomegalovirus (CMV) viremia, and effects on antimicrobial use . Length of hospital stay, 34.5 days vs. 30 days (p=0.19); median NE, 13.85 vs 15.03 days (p=0.007); median PE, 15.5 vs 12 days (p =0.12); ES, 28.5% vs 12.5% (p=0.12); FEN, 85.7% vs 84.3% (p=0.88); aGVHD, 39.2% vs 40.6% (p=0.92); were observed for G-CSFd5 and G-CSFd10, respectively. Although starting G-CSF in the early period after allo-HCT shortened the duration of NE, positive effects on clinical outcomes were not observed. On the contrary, the frequency of ES increased in the group that received GCSF early. © 2023, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.en_US
dc.identifier.doi10.5505/ejm.2023.40121
dc.identifier.endpage731en_US
dc.identifier.issn1301-0883
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85174468521en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage726en_US
dc.identifier.urihttps://doi.org/10.5505/ejm.2023.40121
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14243
dc.identifier.volume28en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherYuzuncu Yil Universitesi Tip Fakultesien_US
dc.relation.ispartofEastern Journal of Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute Lymphobl astic Leukemiaen_US
dc.subjectCOVID-19en_US
dc.subjectFebrile Neutropeniaen_US
dc.subjectLength of Hospital Stayen_US
dc.titleThe Timing of Granulocyte Colony-Stimulating Factor in Hematopoietic Stem Cell Transplant in the Pandemicen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
343 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu